‹ ›
MYP_133808
← PREVIOUS NEXT → BACK
Basic Information
D-MART-1
Anticancer
Binding / Molecular interaction ▸ Binding activity
Immunology ▸ Immunomodulation ▸ Immunogenic
Immunology ▸ MHC/HLA binding
Standard
9 amino acids
C37H67N9O11
Standard
Sequence
AAGIGILTV
Physicochemical Analysis
813.98 Da
5.57
-0.20
-0.39
-0.0227
2.12
0.08
0.78
11.42
184.44
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
316.35
-2.25
11.0
11.0
25.0
57.0
0.0
8.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0103440 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MART-1
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Human plasma: Half-life is 22 s
PaperBrinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326-34. PMID:10495424 https://pubmed.ncbi.nlm.nih.gov/10495424/ PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
RECORD: Rec_0147937 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MART-1
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Asn(β-D-GlcNHAc)
Bio-Activity Profile
Anticancer
Human plasma: Stability increased
PaperBrinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326-34. PMID:10495424 https://pubmed.ncbi.nlm.nih.gov/10495424/ PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
RECORD: Rec_0227926 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MART-1
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Amidation
Bio-Activity Profile
Anticancer
Human plasma: Stability increased
PaperBrinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326-34. PMID:10495424 https://pubmed.ncbi.nlm.nih.gov/10495424/ PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
RECORD: Rec_0243104 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Immunogenic HLA-binding
inhibition of binding of a standard peptide to HLA-A*0201 molecules is 0.5μM
0.5 μM
IC50
VMM5 cytotoxic T-lymphocyte line incubated in human plasma, in vitro; 22 s
PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
RECORD: Rec_0288572 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Asn(β-D-GlcNHAc)
None
Bio-Activity Profile
Immunogenic
VMM5 cytotoxic T-lymphocyte line incubated in human plasma, in vitro; Stability increased seconds
PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 2 of 4